Trial Profile
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2019
Price :
$35
*
At a glance
- Drugs Neurotrophic factor producing mesenchymal stem cell therapy BrainStorm Cell therapeutics (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms NurOwn
- Sponsors Brainstorm Cell Therapeutics
- 20 Nov 2019 Results published in the Brainstorm Cell Therapeutics Media Release
- 18 Nov 2019 Results published in the Neurology
- 03 Oct 2018 According to a Brainstorm Cell therapeutics media release, data from this trial is being presented today at the Northeast Amyotrophic Lateral Sclerosis (NEALS) Conference and the Cell & Gene Meeting on the Mesa Conference (Oct 2018).